Inner medullary cells in vivo can survive and function despite interstitial tonicities of over 1,200 mosmol/kgH 2 O. In contrast, in culture, IMCD3 cells do not survive an acute increase in NaCl concentration above 600 mosmol/kgH 2 O (8) . This greater osmotic tolerance in vivo is partially due to both slower proliferation rates and gradual, slower rate of tonicity changes, as dictated by the need to generate concentrated urine to adjust osmolality of body fluids. These allow cells to adjust more slowly and to initiate compatible osmotic stress responses (10) . A possible explanation for the small amount of cell death in vivo is that there is isovolumetric regulation during the gradual increase in tissue tonicity (due to the accumulation of osmolytes), which prevents cell shrinkage-induced initiation of apoptotic and necrotic pathways (3, 6) . However, the mechanisms that lead to the initiation of programmed cell death or programmed necrosis are still poorly understood. The cell's sensing of a hypertonic environment may involve membrane-spanning receptors, such as integrins (4) . There are still many questions to be answered: How does cell shrinkage activate apoptotic versus necrotic pathways? Which step defines whether caspase-dependent or independent pathways will be activated? Is hypertonicity-mediated cell death important in certain clinical settings, such as NSAID-induced acute kidney injury?
With emerging new tools to study cell death pathways (i.e., triple-knockout mice, conditional tubular knockout systems), the relative contribution of classic apoptotic pathways versus programmed necrosis in hypertonicity-induced cell death will be unraveled (Fig. 1) . Interconnections in signaling pathways, cell cycle regulation, and mechanisms of organelle membrane alterations between these different forms of organized cell Hypertonic stress can activate either receptor-mediated, lysosomal-dependent, or mitochondrial death pathways, which may lead to either programmed necrosis or apoptosis and can be induced either by caspases or in a caspase-independent fashion. APAF1, apoptotic protease activating factor 1. death will likely be found. Enhanced understanding of the regulatory steps and these interconnections open up therapeutic opportunities that might lead to prevention of drug-induced cell injury or age-related impaired kidney function.
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